Synopsis:
Hemanth Surgical Industries Limited has secured a purchase order worth Rs. 82.89 crore from the Central Medical Service Society, Ministry of Health and Family Welfare, to supply Ultraportable Handheld Portable X-ray Machines.
A medical equipment supplier firm recently came into notice after receiving an order from the Central Medical Service Society, Ministry of Health and Family Welfare, for a consideration of Rs.82.89 crore.
Hemant Surgical Industries Ltd valued at a market capitalization of Rs.354.91 crore. The shares were trading at Rs. 339.95, higher than the previous close of Rs. 333.95, and reached the 2 percent upper circuit limit of Rs. 339.95.
Purchase Order
Hemant Surgical Industries Ltd has received a purchase order from the Central Medical Service Society, Ministry of Health and Family Welfare, for a consideration of Rs.82.89 crores to supply Ultraportable Handheld portable X-ray Machines with required utilities and a three-year warranty. The company is required to complete the order in multiple stages by December 31, 2025.
Also Read: Microcap stock jumps 12% after receiving ₹37 Cr order for interior fit-out project
About the company & Financials
Hemant Surgical Industries Limited has over 30 years of experience providing trusted healthcare solutions. The company develops, imports, assembles, and markets a wide range of medical equipment and disposable products, including solutions for renal care, etc. As the exclusive partner for JMS products in India, Hemant Surgical has a strong brand presence both domestically and internationally.
The company witnessed a decline in operating revenue, falling from Rs.58 crore in Q1FY25 to Rs.57.6 crore in Q1FY26. Meanwhile, its net profit fell from Rs.5.8 crore to Rs.4.94 crore. The financial indicators, including an ROE of 13.6 percent and an ROCE of 16.4 percent, suggest the firm is giving moderate returns on shareholder equity and capital employed. The stock has a price-to-earnings ratio of 43.50, much lesser than the industry average of 45.50, it is undervalued compared to its peers.
Written By Jhanavi Sivakumar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
